Exelixis clears debt, turning eye to future growth

05:28 EDT 29 Jun 2017 | BioPharmaDive

Boosted by growing revenues from its kidney cancer drug Cabometyx, Exelixis is wiping its debt clean and betting it can fund growth from operations. 

Original Article: Exelixis clears debt, turning eye to future growth


More From BioPortfolio on "Exelixis clears debt, turning eye to future growth"

Quick Search


Relevant Topics

Diabetes Diabetes Endocrine Obesity Oxycontin Renal Disease Thyroid Disorders Endocrinology is the study of the endocrine glands and the hormones that they secrete (Oxford Medical Dictionary). There are several groups of h...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...